- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Tevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services Initiative | 509 | GlobeNewswire (Europe) | William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 28.05. | Tevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue | 543 | GlobeNewswire (Europe) | WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended... ► Artikel lesen | |
| 21.05. | Tevogen Bio Inc: Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization | 454 | GlobeNewswire (Europe) | WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter... ► Artikel lesen | |
| 20.05. | Tevogen Bio Holdings reports Q1 results; operating loss falls 48% | 3 | Seeking Alpha | ||
| 18.05. | Tevogen reports reduced operating losses in 2025 and Q1 2026 | 1 | Investing.com | ||
| 18.05. | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 95 | GlobeNewswire (Europe) | WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, Since Tevogen's 2024 public listing, we have remained focused on... ► Artikel lesen | |
| 15.05. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 12.05. | Tevogen Bio Inc: Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close | 270 | GlobeNewswire (Europe) | WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private... ► Artikel lesen | |
| 30.04. | Tevogen Bio Holdings Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 22.04. | Tevogen Bio Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Tevogen Bio Holdings Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 26.03. | Tevogen Bio Inc: Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth | 309 | GlobeNewswire (Europe) | Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen's position in oncology, rare diseases, and medical devicesTarget CRO operates... ► Artikel lesen | |
| 25.03. | Tevogen Bio erfüllt nach Aktienzusammenlegung wieder Nasdaq-Anforderungen | 3 | Investing.com Deutsch | ||
| 25.03. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.03. | Tevogen Bio Inc: Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement | 218 | GlobeNewswire (Europe) | WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market... ► Artikel lesen | |
| 13.03. | Tevogen Bio Inc: Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization | 392 | GlobeNewswire (Europe) | Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next... ► Artikel lesen | |
| 13.03. | Tevogen Bio Inc: Tevogen.AI Reports Advancements in PredicTcell Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure | 435 | GlobeNewswire (Europe) | WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform... ► Artikel lesen | |
| 11.03. | Tevogen Bio Inc: Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform | 2 | GlobeNewswire (USA) | ||
| 09.03. | Tevogen Bio Inc: Tevogen Names Leadership Team to Execute Diversified Growth Strategy | 412 | GlobeNewswire (Europe) | WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN) today announced the appointment of interim leaders across its core business verticals... ► Artikel lesen | |
| 06.03. | Tevogen Bio Inc: Letter to Shareholders from CEO Dr. Ryan Saadi | 719 | GlobeNewswire (Europe) | WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN). Dear Shareholders, As we continue executing on Tevogen's long-term strategy to evolve... ► Artikel lesen |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,884 | +2,43 % | Evotec nach dem Absturz: Droht noch mehr Druck auf die Aktie? | Die Aktie von Evotec bleibt nach den jüngsten Geschäftszahlen unter Druck. Zwar wächst das operative Geschäft weiter, doch sinkende Gewinne und hohe Investitionen sorgen für Verunsicherung bei Anlegern.... ► Artikel lesen | |
| QIAGEN | 31,765 | -0,67 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| VALNEVA | 2,312 | +1,09 % | EXKLUSIV zu Valneva: Was große Adressen heute bereits wissen - Meine Analyse im Detail | ||
| AMGEN | 303,60 | -1,09 % | Amgen loses in Harbour antibody patent case, ordered to pay $20M+ | ||
| NOVAVAX | 7,860 | +2,61 % | Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade | ||
| PALATIN TECHNOLOGIES | 12,690 | -8,84 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 526,40 | -0,45 % | Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy | ||
| VIVOSIM LABS | 1,200 | +5,26 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,997 | +4,35 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders | RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,780 | +12,62 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,580 | -0,63 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results | TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,560 | -1,65 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia | Study met primary endpoint, exceeding expectations with a highly statistically significant improvement in annualized growth velocity (AGV, change from baseline)... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,730 | +1,36 % | Arbutus Biopharma Corporation: Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update | Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 65,30 | +1,37 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen |
TEVOGEN BIO HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,640 (-5,95 %) liegt der Kurs bei 10,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.